Assertio Holdings, Inc.

Assertio Holdings, Inc. (ASRT)

$6.43

+0.1

(+1.58%)

Market is closed - opens 7 PM, 02 Jun 2023

Insights on Assertio Holdings, Inc.

  • Decreasing Revenue

    Revenue is down for the last 2 quarters, 50.35M → 42.46M (in $), with an average decrease of 15.7% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 88.55M → -3.48M (in $), with an average decrease of 103.9% per quarter

Performance

  • $6.30
    $6.56
    $6.43
    downward going graph

    2.02%

    Downside

    Day's Volatility :3.89%

    Upside

    1.91%

    downward going graph
  • $2.07
    $8.01
    $6.43
    downward going graph

    67.81%

    Downside

    52 Weeks Volatility :74.16%

    Upside

    19.73%

    downward going graph

Returns

PeriodAssertio Holdings, Inc.Sector (Health Care)Index (Russel 2000)
3 Months
6.03%
0.7%
-6.8%
6 Months
111.0%
-8.3%
-6.0%
1 Year
104.85%
-1.9%
-4.6%
3 Years
58.25%
25.3%
25.9%

Highlights

Market Capitalization
359.6M
Book Value
$4.5
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
1.75
PE Ratio
3.69
PEG Ratio
0.62
Wall Street Target Price
9.75
Profit Margin
59.86%
Operating Margin TTM
35.37%
Return On Assets TTM
9.52%
Return On Equity TTM
53.56%
Revenue TTM
162.2M
Revenue Per Share TTM
3.35
Quarterly Revenue Growth YOY
16.2%
Gross Profit TTM
138.3M
EBITDA
88.5M
Diluted Eps TTM
1.75
Quarterly Earnings Growth YOY
12.11
EPS Estimate Current Year
0.37
EPS Estimate Next Year
0.61
EPS Estimate Current Quarter
0.13
EPS Estimate Next Quarter
0.14

Analyst Recommendation

Buy
    88%Buy
    11%Hold
    0
    0%Sell
Based on 9 Wall street analysts offering stock ratings for Assertio Holdings, Inc.(by analysts ranked 0 to 5 stars)
Based on 9 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
8
8
8
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 51.63%

Current $6.43
Target $9.75

Company Financials

FY17Y/Y Change
Revenue
380.7M
↓ 16.49%
Net Income
-102.5M
↑ 15.53%
Net Profit Margin
-26.92%
↓ 7.46%
FY18Y/Y Change
Revenue
311.8M
↓ 18.11%
Net Income
36.9M
↓ 136.01%
Net Profit Margin
11.84%
↑ 38.76%
FY19Y/Y Change
Revenue
229.5M
↓ 26.39%
Net Income
-217.2M
↓ 688.49%
Net Profit Margin
-94.64%
↓ 106.48%
FY20Y/Y Change
Revenue
106.3M
↓ 53.69%
Net Income
-28.1M
↓ 87.04%
Net Profit Margin
-26.48%
↑ 68.16%
FY21Y/Y Change
Revenue
111.0M
↑ 4.46%
Net Income
-1.3M
↓ 95.45%
Net Profit Margin
-1.15%
↑ 25.33%
FY22Y/Y Change
Revenue
156.2M
↑ 40.73%
Net Income
109.6M
↓ 8657.77%
Net Profit Margin
70.17%
↑ 71.32%
Q4 FY21Q/Q Change
Revenue
33.3M
↑ 30.84%
Net Income
4.6M
↑ 23.25%
Net Profit Margin
13.82%
↓ 0.85%
Q1 FY22Q/Q Change
Revenue
36.5M
↑ 9.63%
Net Income
9.1M
↑ 96.79%
Net Profit Margin
24.81%
↑ 10.99%
Q2 FY22Q/Q Change
Revenue
35.1M
↓ 3.85%
Net Income
7.8M
↓ 13.57%
Net Profit Margin
22.3%
↓ 2.51%
Q3 FY22Q/Q Change
Revenue
34.2M
↓ 2.62%
Net Income
4.2M
↓ 46.72%
Net Profit Margin
12.2%
↓ 10.1%
Q4 FY22Q/Q Change
Revenue
50.4M
↑ 47.18%
Net Income
88.6M
↑ 2021.49%
Net Profit Margin
175.86%
↑ 163.66%
Q1 FY23Q/Q Change
Revenue
42.5M
↓ 15.66%
Net Income
-3.5M
↓ 103.93%
Net Profit Margin
-8.2%
↓ 184.06%
FY17Y/Y Change
Total Assets
1.0B
↓ 15.24%
Total Liabilities
869.1M
↓ 10.82%
FY18Y/Y Change
Total Assets
932.9M
↓ 10.18%
Total Liabilities
712.5M
↓ 18.02%
FY19Y/Y Change
Total Assets
527.2M
↓ 43.49%
Total Liabilities
469.2M
↓ 34.15%
FY20Y/Y Change
Total Assets
303.3M
↓ 42.47%
Total Liabilities
247.8M
↓ 47.2%
FY21Y/Y Change
Total Assets
326.5M
↑ 7.67%
Total Liabilities
224.1M
↓ 9.54%
FY22Y/Y Change
Total Assets
413.9M
↑ 26.75%
Total Liabilities
188.2M
↓ 16.04%
Q4 FY21Q/Q Change
Total Assets
326.5M
↑ 9.1%
Total Liabilities
224.1M
↑ 10.71%
Q1 FY22Q/Q Change
Total Assets
339.1M
↑ 3.85%
Total Liabilities
227.3M
↑ 1.4%
Q2 FY22Q/Q Change
Total Assets
322.0M
↓ 5.06%
Total Liabilities
193.6M
↓ 14.81%
Q3 FY22Q/Q Change
Total Assets
323.3M
↑ 0.42%
Total Liabilities
188.4M
↓ 2.67%
Q4 FY22Q/Q Change
Total Assets
413.9M
↑ 28.01%
Total Liabilities
188.2M
↓ 0.13%
Q1 FY23Q/Q Change
Total Assets
414.3M
↑ 0.09%
Total Liabilities
163.6M
↓ 13.06%
FY17Y/Y Change
Operating Cash Flow
62.2M
↓ 5.09%
Investing Cash Flow
57.9M
↑ 27.14%
Financing Cash Flow
-110.9M
↑ 17.45%
FY18Y/Y Change
Operating Cash Flow
72.5M
↑ 16.62%
Investing Cash Flow
-7.1M
↓ 112.23%
Financing Cash Flow
-81.4M
↓ 26.64%
FY19Y/Y Change
Operating Cash Flow
90.5M
↑ 24.8%
Investing Cash Flow
-1.5M
↓ 79.09%
Financing Cash Flow
-157.8M
↑ 94.02%
FY20Y/Y Change
Operating Cash Flow
-65.6M
↓ 172.48%
Investing Cash Flow
512.8M
↓ 34725.32%
Financing Cash Flow
-468.6M
↑ 196.86%
FY21Y/Y Change
Operating Cash Flow
5.5M
↓ 108.42%
Investing Cash Flow
-18.5M
↓ 103.61%
Financing Cash Flow
29.0M
↓ 106.19%
Q4 FY21Q/Q Change
Operating Cash Flow
4.1M
↓ 11.24%
Investing Cash Flow
-18.5M
↑ 0.0%
Financing Cash Flow
-7.5M
↑ 2012.92%
Q1 FY22Q/Q Change
Operating Cash Flow
27.4M
↑ 563.91%
Investing Cash Flow
-404.0K
↓ 97.82%
Financing Cash Flow
-2.4M
↓ 67.52%
Q2 FY22Q/Q Change
Operating Cash Flow
14.4M
↓ 47.39%
Investing Cash Flow
-16.1M
↑ 3888.61%
Financing Cash Flow
-7.4M
↑ 204.58%
Q3 FY22Q/Q Change
Operating Cash Flow
10.0M
↓ 30.39%
Investing Cash Flow
-371.0K
↓ 97.7%
Financing Cash Flow
2.9M
↓ 138.81%

Technicals Summary

Sell

Neutral

Buy

Assertio Holdings, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Assertio Holdings, Inc.
Assertio Holdings, Inc.
10.09%
111.0%
104.85%
58.25%
-80.32%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
-13.93%
-29.12%
-3.47%
-27.45%
-9.1%
Zoetis Inc.
Zoetis Inc.
-9.22%
4.07%
-2.4%
17.83%
90.83%
Viatris Inc.
Viatris Inc.
-2.24%
-18.59%
-24.19%
-44.0%
-44.0%
Catalent, Inc.
Catalent, Inc.
-25.72%
-28.72%
-64.37%
-51.42%
-6.08%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Assertio Holdings, Inc.
Assertio Holdings, Inc.
3.69
3.69
0.62
0.37
0.54
0.1
0.0
4.5
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
145.34
145.34
1.87
2.1
0.04
0.08
0.0
17.28
Zoetis Inc.
Zoetis Inc.
36.41
36.41
3.53
5.4
0.45
0.13
0.01
9.72
Viatris Inc.
Viatris Inc.
5.8
5.8
NA
2.95
0.09
0.03
0.05
17.45
Catalent, Inc.
Catalent, Inc.
15.88
15.88
1.18
1.37
0.09
0.04
0.0
27.29
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Assertio Holdings, Inc.
Assertio Holdings, Inc.
Buy
$359.6M
-80.32%
3.69
59.86%
Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc.
Buy
$8.8B
-9.1%
145.34
4.0%
Zoetis Inc.
Zoetis Inc.
Buy
$74.4B
90.83%
36.41
25.59%
Viatris Inc.
Viatris Inc.
Hold
$10.9B
-44.0%
5.8
12.05%
Catalent, Inc.
Catalent, Inc.
Buy
$6.5B
-6.08%
15.88
8.62%

Institutional Holdings

  • Vanguard Group Inc

    4.34%
  • Renaissance Technologies Corp

    3.62%
  • Acadian Asset Management LLC

    2.06%
  • LITTLEJOHN & CO LLC

    1.70%
  • Millennium Management LLC

    1.69%
  • BlackRock Inc

    1.68%

Company Information

Organization
Assertio Holdings, Inc.
Employees
30
CEO
Mr. Daniel A. Peisert
Industry
Health Technology

FAQs